Interpace Biosciences, Inc.
IDXG
$0.9077
-$0.0823-8.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -126.26% | 132.63% | 41.63% | 308.47% | 1,292.57% |
| Total Depreciation and Amortization | 5.85% | 18.75% | 13.44% | -46.31% | -66.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,957.14% | -108.20% | -42.63% | 13.30% | -98.07% |
| Change in Net Operating Assets | 159.61% | 42.46% | -42.44% | -83.32% | -73.69% |
| Cash from Operations | -62.96% | 2,229.31% | 3.86% | 91.49% | 241.61% |
| Capital Expenditure | -2.03% | -- | 9.15% | -243.42% | -77.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2.03% | -- | 9.15% | -250.00% | 13.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 50.00% | -150.00% | -- | 0.00% | -185.71% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -43.75% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 93.56% | -- | -- |
| Cash from Financing | 49.35% | -150.00% | 32.58% | 0.00% | -185.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.48% | 61.37% | 57.50% | 300.00% | -53.38% |